T1	Participants 347 394	548 patients enrolled, 281 (51%) were evaluable
T2	Participants 473 560	(100/139) for the evaluable patients treated with cefdinir and cefprozil, respectively.
T3	Participants 1063 1083	two treatment groups
T4	Participants 1142 1224	patients treated with cefdinir (17%) than for patients treated with cefprozil (6%)
T5	Participants 1413 1468	patients with acute exacerbations of chronic bronchitis
